Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adjustment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    354 result(s) found for: Adjustment. Displaying page 2 of 18.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-003195-13 Sponsor Protocol Number: 02/06/2021/2.0 Start Date*: 2021-06-23
    Sponsor Name:Fakultní nemocnice Ostrava
    Full Title: Importance of therapeutic monitoring of orally administered disease-modifying drugs used in the treatment of multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000781-15 Sponsor Protocol Number: COVFATI Start Date*: 2021-12-14
    Sponsor Name:Amsterdam UMC VUmc
    Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19
    Medical condition: Chronic fatigue after COVID-19 infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002455-26 Sponsor Protocol Number: IRON-CMR Start Date*: 2014-09-20
    Sponsor Name:Karolinska Institute
    Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.
    Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004956-32 Sponsor Protocol Number: E2090-S082-404 Start Date*: 2017-02-23
    Sponsor Name:Eisai Korea Inc.
    Full Title: A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children with Newly Diagnosed Epilepsy as Monotherapy
    Medical condition: Epilepsy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-003986-25 Sponsor Protocol Number: ADAMPA Start Date*: 2017-05-05
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Impact of self-measurement of blood pressure and self-adjustment of antihypertensive medication in the control of hypertension and adherence to treatment. A pragmatic, randomized, controlled clinic...
    Medical condition: Arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001919-39 Sponsor Protocol Number: 48890 Start Date*: 2014-08-27
    Sponsor Name:Erasmus MC
    Full Title: Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study
    Medical condition: Inflammatory bowel disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001146-13 Sponsor Protocol Number: A 001 Start Date*: 2006-05-18
    Sponsor Name:University Hospital of Heidelberg
    Full Title: "Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit"
    Medical condition: hospitalised patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004151-35 Sponsor Protocol Number: PK-1 Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Heidelberg
    Full Title: Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy
    Medical condition: 12 Patients (full term neonates with 7 to 28 days of age) with infections of the skin, the nails or the respiratory tract.
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005270-10 Sponsor Protocol Number: NALISO-II-20-1 Start Date*: 2021-08-18
    Sponsor Name:LABORATOIRES SMB S.A
    Full Title: A randomized, partially blinded, parallel study to evaluate the effects of nacystelyn in combination with isotretinoin in the treatment of recalcitrant acne vulgaris.
    Medical condition: Recalcitrant acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002631-15 Sponsor Protocol Number: BECRO/RESP/BREATH-PD Start Date*: 2018-09-04
    Sponsor Name:RESPIRENT Pharmaceuticals
    Full Title: A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respiren...
    Medical condition: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002977-27 Sponsor Protocol Number: BECRO/RESP/AERO-PD Start Date*: 2023-01-23
    Sponsor Name:Respirent Pharmaceuticals Co. Ltd
    Full Title: A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respiren...
    Medical condition: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005674-47 Sponsor Protocol Number: CL3-20098-050 Start Date*: 2007-10-26
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    10.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004008-19 Sponsor Protocol Number: CL3-20098-045 Start Date*: 2005-08-23
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    3. SERVIER Research and Development ICTR (For United Kingdom only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel...
    Medical condition: Severe Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004881-17 Sponsor Protocol Number: CL3-20098-047 Start Date*: 2006-05-01
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...
    Medical condition: Major depressive episode in the framework of bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10004939 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) ES (Completed) FI (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002112-27 Sponsor Protocol Number: MD1003CT2013-01MS-ON Start Date*: Information not available in EudraCT
    Sponsor Name:MEDDAY SAS
    Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study
    Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    18.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-004562-10 Sponsor Protocol Number: BUM-5/GVH Start Date*: 2009-07-29
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wi...
    Medical condition: Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) FR (Completed) SE (Completed) IT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005509-79 Sponsor Protocol Number: VR040/2/003 Start Date*: 2006-12-21
    Sponsor Name:Vectura Group plc
    Full Title: A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patient...
    Medical condition: Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor “off” periods
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002754-22 Sponsor Protocol Number: BUM-4/GVH Start Date*: 2006-03-14
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: An open, randomized, multicentre phase II pilot study to evaluate the efficacy of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD using different application durati...
    Medical condition: oral chronic graft versus host disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005438-57 Sponsor Protocol Number: HGWH0008 Start Date*: 2008-11-19
    Sponsor Name:Academic Medical Centre
    Full Title: Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer
    Medical condition: The main group are patients with renal cell cancer currently being or about to be treated with sunitinib. Other diseases with efficacy of sunitinib are Gastro Intestinal Stromal cell tumour (GIST).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 06:44:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA